Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease

Mei Shao, Zahid Hussain, Hnin Ei Thu, Shahzeb Khan, Haliza Katas, Tarek A. Ahmed, Minaketan Tripathy, Jing Leng, Hua Li Qin, Bukhari Syed Nasir Abbas

Research output: Contribution to journalReview article

19 Citations (Scopus)

Abstract

Atopic dermatitis (AD) is a chronically relapsing skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin-E (IgE), T-lymphocytes and mast cells. The key pathophysiological factors causing this disease are immunological disorders and the compromised epidermal barrier integrity. Pruritus, intense itching, psychological stress, deprived physical and mental performance and sleep disturbance are the hallmark features of this dermatological complication. Preventive interventions which include educational programs, avoidance of allergens, exclusive care towards skin, and the rational selection of therapeutic regimen play key roles in the treatment of dermatosis. In last two decades, it is evident from a plethora of studies that scientific focus is being driven from conventional therapies to the advanced nanocarrier-based regimen for an effective management of AD. These nanocarriers which include polymeric nanoparticles (NPs), hydrogel NPs, liposomes, ethosomes, solid lipid nanoparticles (SLNs) and nanoemulsion, provide efficient roles for the target specific delivery of the therapeutic payload. The success of these targeted therapies is due to their pharmaceutical versatility, longer retention time at the target site, avoiding off-target effects and preventing premature degradation of the incorporated drugs. The present review was therefore aimed to summarise convincing evidence for the therapeutic superiority of advanced nanocarrier-mediated strategies over the conventional therapies used in the treatment of AD.

Original languageEnglish
Pages (from-to)475-491
Number of pages17
JournalColloids and Surfaces B: Biointerfaces
Volume147
DOIs
Publication statusPublished - 1 Nov 2016

Fingerprint

dermatitis
Drug Delivery Systems
Disease Management
therapy
delivery
drugs
Nanoparticles
mental performance
nanoparticles
itching
Skin
disorders
Pharmaceutical Preparations
Allergens
sleep
Atopic Dermatitis
T-cells
Liposomes
avoidance
Hydrogel

Keywords

  • Advanced nanocarrier-based therapies
  • Atopic dermatitis
  • Ethosomes
  • Liposomes
  • Nanoemulsion
  • Polymeric nanoparticles
  • Solid lipid nanoparticles

ASJC Scopus subject areas

  • Biotechnology
  • Medicine(all)
  • Surfaces and Interfaces
  • Physical and Theoretical Chemistry
  • Colloid and Surface Chemistry

Cite this

Drug nanocarrier, the future of atopic diseases : Advanced drug delivery systems and smart management of disease. / Shao, Mei; Hussain, Zahid; Thu, Hnin Ei; Khan, Shahzeb; Katas, Haliza; Ahmed, Tarek A.; Tripathy, Minaketan; Leng, Jing; Qin, Hua Li; Syed Nasir Abbas, Bukhari.

In: Colloids and Surfaces B: Biointerfaces, Vol. 147, 01.11.2016, p. 475-491.

Research output: Contribution to journalReview article

Shao, M, Hussain, Z, Thu, HE, Khan, S, Katas, H, Ahmed, TA, Tripathy, M, Leng, J, Qin, HL & Syed Nasir Abbas, B 2016, 'Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease', Colloids and Surfaces B: Biointerfaces, vol. 147, pp. 475-491. https://doi.org/10.1016/j.colsurfb.2016.08.027
Shao, Mei ; Hussain, Zahid ; Thu, Hnin Ei ; Khan, Shahzeb ; Katas, Haliza ; Ahmed, Tarek A. ; Tripathy, Minaketan ; Leng, Jing ; Qin, Hua Li ; Syed Nasir Abbas, Bukhari. / Drug nanocarrier, the future of atopic diseases : Advanced drug delivery systems and smart management of disease. In: Colloids and Surfaces B: Biointerfaces. 2016 ; Vol. 147. pp. 475-491.
@article{8a9131453c29403797c6546df3433b3c,
title = "Drug nanocarrier, the future of atopic diseases: Advanced drug delivery systems and smart management of disease",
abstract = "Atopic dermatitis (AD) is a chronically relapsing skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin-E (IgE), T-lymphocytes and mast cells. The key pathophysiological factors causing this disease are immunological disorders and the compromised epidermal barrier integrity. Pruritus, intense itching, psychological stress, deprived physical and mental performance and sleep disturbance are the hallmark features of this dermatological complication. Preventive interventions which include educational programs, avoidance of allergens, exclusive care towards skin, and the rational selection of therapeutic regimen play key roles in the treatment of dermatosis. In last two decades, it is evident from a plethora of studies that scientific focus is being driven from conventional therapies to the advanced nanocarrier-based regimen for an effective management of AD. These nanocarriers which include polymeric nanoparticles (NPs), hydrogel NPs, liposomes, ethosomes, solid lipid nanoparticles (SLNs) and nanoemulsion, provide efficient roles for the target specific delivery of the therapeutic payload. The success of these targeted therapies is due to their pharmaceutical versatility, longer retention time at the target site, avoiding off-target effects and preventing premature degradation of the incorporated drugs. The present review was therefore aimed to summarise convincing evidence for the therapeutic superiority of advanced nanocarrier-mediated strategies over the conventional therapies used in the treatment of AD.",
keywords = "Advanced nanocarrier-based therapies, Atopic dermatitis, Ethosomes, Liposomes, Nanoemulsion, Polymeric nanoparticles, Solid lipid nanoparticles",
author = "Mei Shao and Zahid Hussain and Thu, {Hnin Ei} and Shahzeb Khan and Haliza Katas and Ahmed, {Tarek A.} and Minaketan Tripathy and Jing Leng and Qin, {Hua Li} and {Syed Nasir Abbas}, Bukhari",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.colsurfb.2016.08.027",
language = "English",
volume = "147",
pages = "475--491",
journal = "Colloids and Surfaces B: Biointerfaces",
issn = "0927-7765",
publisher = "Elsevier",

}

TY - JOUR

T1 - Drug nanocarrier, the future of atopic diseases

T2 - Advanced drug delivery systems and smart management of disease

AU - Shao, Mei

AU - Hussain, Zahid

AU - Thu, Hnin Ei

AU - Khan, Shahzeb

AU - Katas, Haliza

AU - Ahmed, Tarek A.

AU - Tripathy, Minaketan

AU - Leng, Jing

AU - Qin, Hua Li

AU - Syed Nasir Abbas, Bukhari

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Atopic dermatitis (AD) is a chronically relapsing skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin-E (IgE), T-lymphocytes and mast cells. The key pathophysiological factors causing this disease are immunological disorders and the compromised epidermal barrier integrity. Pruritus, intense itching, psychological stress, deprived physical and mental performance and sleep disturbance are the hallmark features of this dermatological complication. Preventive interventions which include educational programs, avoidance of allergens, exclusive care towards skin, and the rational selection of therapeutic regimen play key roles in the treatment of dermatosis. In last two decades, it is evident from a plethora of studies that scientific focus is being driven from conventional therapies to the advanced nanocarrier-based regimen for an effective management of AD. These nanocarriers which include polymeric nanoparticles (NPs), hydrogel NPs, liposomes, ethosomes, solid lipid nanoparticles (SLNs) and nanoemulsion, provide efficient roles for the target specific delivery of the therapeutic payload. The success of these targeted therapies is due to their pharmaceutical versatility, longer retention time at the target site, avoiding off-target effects and preventing premature degradation of the incorporated drugs. The present review was therefore aimed to summarise convincing evidence for the therapeutic superiority of advanced nanocarrier-mediated strategies over the conventional therapies used in the treatment of AD.

AB - Atopic dermatitis (AD) is a chronically relapsing skin inflammatory disorder characterized by perivascular infiltration of immunoglobulin-E (IgE), T-lymphocytes and mast cells. The key pathophysiological factors causing this disease are immunological disorders and the compromised epidermal barrier integrity. Pruritus, intense itching, psychological stress, deprived physical and mental performance and sleep disturbance are the hallmark features of this dermatological complication. Preventive interventions which include educational programs, avoidance of allergens, exclusive care towards skin, and the rational selection of therapeutic regimen play key roles in the treatment of dermatosis. In last two decades, it is evident from a plethora of studies that scientific focus is being driven from conventional therapies to the advanced nanocarrier-based regimen for an effective management of AD. These nanocarriers which include polymeric nanoparticles (NPs), hydrogel NPs, liposomes, ethosomes, solid lipid nanoparticles (SLNs) and nanoemulsion, provide efficient roles for the target specific delivery of the therapeutic payload. The success of these targeted therapies is due to their pharmaceutical versatility, longer retention time at the target site, avoiding off-target effects and preventing premature degradation of the incorporated drugs. The present review was therefore aimed to summarise convincing evidence for the therapeutic superiority of advanced nanocarrier-mediated strategies over the conventional therapies used in the treatment of AD.

KW - Advanced nanocarrier-based therapies

KW - Atopic dermatitis

KW - Ethosomes

KW - Liposomes

KW - Nanoemulsion

KW - Polymeric nanoparticles

KW - Solid lipid nanoparticles

UR - http://www.scopus.com/inward/record.url?scp=84984782982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84984782982&partnerID=8YFLogxK

U2 - 10.1016/j.colsurfb.2016.08.027

DO - 10.1016/j.colsurfb.2016.08.027

M3 - Review article

C2 - 27592075

AN - SCOPUS:84984782982

VL - 147

SP - 475

EP - 491

JO - Colloids and Surfaces B: Biointerfaces

JF - Colloids and Surfaces B: Biointerfaces

SN - 0927-7765

ER -